Toward personalized medicine of lung cancer: Response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation

Paul H. Hartel, James V. Hartel, Julie C. Fanburg-Smith, R. Wayde Gilmore, Donald Fleming, Steve Barnett, Ronald Mudry, John E. Parker

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We evaluated clinical parameters, histomorphology, and thyroid transcription factor 1 (TTF-1) immunoreactivity in 40 epidermal growth factor receptor (EGFR) mutation- and anaplastic lymphoma kinase (ALK) rearrangement-negative invasive pulmonary adenocarcinomas. Tumors were histomorphologically quantitated by a pulmonary pathologist and TTF-1 immunohistochemistry applied. EGFR mutation and ALK rearrangement status was determined with polymerase chain reaction/DNA sequencing and fluorescence in situ hybridization, respectively. Treatment response was related to type of treatment (P <.005) and clinical stage (P =.001). EGFR mutation- and ALK rearrangement-negative pulmonary adenocarcinomas containing papillary/ micropapillary histology showed greater morphologic heterogeneity (P <.001), greater TTF-1 immunoreactivity (P =.004), and were more common in treatment responders (P <.05). These findings support that patients with pulmonary adenocarcinomas that are subject to nontargeted therapies may respond to treatment as a function of tumor cell differentiation with TTF-1 as a potential biomarker of this response.

Original languageEnglish (US)
Pages (from-to)224-228
Number of pages5
JournalInternational Journal of Surgical Pathology
Volume21
Issue number3
DOIs
StatePublished - Jun 1 2013

Fingerprint

Precision Medicine
Cell Differentiation
Lung Neoplasms
Epidermal Growth Factor Receptor
Neoplasms
Mutation
Therapeutics
Fluorescence In Situ Hybridization
DNA Sequence Analysis
Histology
Biomarkers
Immunohistochemistry
Adenocarcinoma of lung
Polymerase Chain Reaction
Lung
thyroid nuclear factor 1
anaplastic lymphoma kinase

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Surgery
  • Pathology and Forensic Medicine

Cite this

Hartel, Paul H. ; Hartel, James V. ; Fanburg-Smith, Julie C. ; Gilmore, R. Wayde ; Fleming, Donald ; Barnett, Steve ; Mudry, Ronald ; Parker, John E. / Toward personalized medicine of lung cancer : Response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation. In: International Journal of Surgical Pathology. 2013 ; Vol. 21, No. 3. pp. 224-228.
@article{270909d2160c41c9a6dff0df8c8c8eb8,
title = "Toward personalized medicine of lung cancer: Response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation",
abstract = "We evaluated clinical parameters, histomorphology, and thyroid transcription factor 1 (TTF-1) immunoreactivity in 40 epidermal growth factor receptor (EGFR) mutation- and anaplastic lymphoma kinase (ALK) rearrangement-negative invasive pulmonary adenocarcinomas. Tumors were histomorphologically quantitated by a pulmonary pathologist and TTF-1 immunohistochemistry applied. EGFR mutation and ALK rearrangement status was determined with polymerase chain reaction/DNA sequencing and fluorescence in situ hybridization, respectively. Treatment response was related to type of treatment (P <.005) and clinical stage (P =.001). EGFR mutation- and ALK rearrangement-negative pulmonary adenocarcinomas containing papillary/ micropapillary histology showed greater morphologic heterogeneity (P <.001), greater TTF-1 immunoreactivity (P =.004), and were more common in treatment responders (P <.05). These findings support that patients with pulmonary adenocarcinomas that are subject to nontargeted therapies may respond to treatment as a function of tumor cell differentiation with TTF-1 as a potential biomarker of this response.",
author = "Hartel, {Paul H.} and Hartel, {James V.} and Fanburg-Smith, {Julie C.} and Gilmore, {R. Wayde} and Donald Fleming and Steve Barnett and Ronald Mudry and Parker, {John E.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1177/1066896913486694",
language = "English (US)",
volume = "21",
pages = "224--228",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "3",

}

Toward personalized medicine of lung cancer : Response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation. / Hartel, Paul H.; Hartel, James V.; Fanburg-Smith, Julie C.; Gilmore, R. Wayde; Fleming, Donald; Barnett, Steve; Mudry, Ronald; Parker, John E.

In: International Journal of Surgical Pathology, Vol. 21, No. 3, 01.06.2013, p. 224-228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Toward personalized medicine of lung cancer

T2 - Response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation

AU - Hartel, Paul H.

AU - Hartel, James V.

AU - Fanburg-Smith, Julie C.

AU - Gilmore, R. Wayde

AU - Fleming, Donald

AU - Barnett, Steve

AU - Mudry, Ronald

AU - Parker, John E.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - We evaluated clinical parameters, histomorphology, and thyroid transcription factor 1 (TTF-1) immunoreactivity in 40 epidermal growth factor receptor (EGFR) mutation- and anaplastic lymphoma kinase (ALK) rearrangement-negative invasive pulmonary adenocarcinomas. Tumors were histomorphologically quantitated by a pulmonary pathologist and TTF-1 immunohistochemistry applied. EGFR mutation and ALK rearrangement status was determined with polymerase chain reaction/DNA sequencing and fluorescence in situ hybridization, respectively. Treatment response was related to type of treatment (P <.005) and clinical stage (P =.001). EGFR mutation- and ALK rearrangement-negative pulmonary adenocarcinomas containing papillary/ micropapillary histology showed greater morphologic heterogeneity (P <.001), greater TTF-1 immunoreactivity (P =.004), and were more common in treatment responders (P <.05). These findings support that patients with pulmonary adenocarcinomas that are subject to nontargeted therapies may respond to treatment as a function of tumor cell differentiation with TTF-1 as a potential biomarker of this response.

AB - We evaluated clinical parameters, histomorphology, and thyroid transcription factor 1 (TTF-1) immunoreactivity in 40 epidermal growth factor receptor (EGFR) mutation- and anaplastic lymphoma kinase (ALK) rearrangement-negative invasive pulmonary adenocarcinomas. Tumors were histomorphologically quantitated by a pulmonary pathologist and TTF-1 immunohistochemistry applied. EGFR mutation and ALK rearrangement status was determined with polymerase chain reaction/DNA sequencing and fluorescence in situ hybridization, respectively. Treatment response was related to type of treatment (P <.005) and clinical stage (P =.001). EGFR mutation- and ALK rearrangement-negative pulmonary adenocarcinomas containing papillary/ micropapillary histology showed greater morphologic heterogeneity (P <.001), greater TTF-1 immunoreactivity (P =.004), and were more common in treatment responders (P <.05). These findings support that patients with pulmonary adenocarcinomas that are subject to nontargeted therapies may respond to treatment as a function of tumor cell differentiation with TTF-1 as a potential biomarker of this response.

UR - http://www.scopus.com/inward/record.url?scp=84878226873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878226873&partnerID=8YFLogxK

U2 - 10.1177/1066896913486694

DO - 10.1177/1066896913486694

M3 - Article

C2 - 23637254

AN - SCOPUS:84878226873

VL - 21

SP - 224

EP - 228

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 3

ER -